Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada

Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada

Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada

HC0069

Overview

Background
  • Nirmatrelvir-ritonavir (Paxlovid) and remdesivir are two antiviral therapies indicated for the treatment of non-hospitalized adult patients with mild to moderate COVID-19.
Aims of the study
  • The purpose of this study is to describe the use of Paxlovid and remdesivir in the outpatient setting across Canadian provinces for which data are readily available, and describe the characteristics of patients receiving these therapies.
  • This project is a collaboration with ADTEC and INESSS.

Manuscripts

Presentations

Project Team

Project Lead
Michael Paterson MSc
Research Assistant
Audray St-Jean MSc
Site Investigator
Donica Janzen PhD
Saskatchewan
Site Investigator
Mike Benigeri
Quebec
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Alan Katz MBChB, MSc, CCFP
Manitoba
Site Investigator
Colin R. Dormuth ScD
British Columbia
Site Investigator
Paul Ronksley PhD
Alberta
Analyst
Xinya Lu PhD
Saskatchewan
Analyst
Jean-Luc Kaboré
Quebec
Analyst
Houssem Missaoui
Quebec
Analyst
Fangyun Wu MSc
Ontario
Analyst
Ruby Sheng
Ontario
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Sylvia Aponte-Hao
Alberta